// App-Quantinova.ai

: Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Peter C.C. Fong

Principal Investigators

  • Alexandra Drakaki

  • Christophe Massard

  • William R. Berry

  • Emanuela Romano

  • Johann S. De Bono

  • Susan Feyerabend

  • Leonard Joseph Appleman

  • Henry Jacob Conter

  • Srikala S. Sridhar

  • Neal D. Shore

  • Mark David Linch

  • Anthony Joshua

  • Howard Gurney

  • Haiyan Wu

  • Charles Schloss

  • Christian Heinrich Poehlein

  • Evan Y. Yu

Medical Centers

  • Auckland City Hospital, Auckland, New Zealand

  • Rechts der Isar University Hospital, Technical University of Munich, Munich, Germany

  • University of California, Los Angeles, Los Angeles, CA

  • Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France

  • Duke University College of Medicine, Durham, NC

  • Institut Curie, Paris Cedex, France

  • The Royal Marsden Hospital, London, United Kingdom

  • Studienpraxis Urologie, Nurtingen, Germany

  • University of Pittsburgh Medical Center, Pittsburgh, PA

  • University of Western Ontario, London, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • The Kinghorn Cancer Centre, St Vincents Hospital, Sydney, Australia

  • Macquarie University Hospital, Sydney, Australia

  • Merck & Co., Inc., Kenilworth, NJ

  • University of Washington, Seattle, WA

Locations

  • New Zealand

  • Germany

  • United States

  • France

  • United Kingdom

  • Canada

  • Australia

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Genetic Disorder

  • Nephrology

  • Musculoskeletal

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Pembrolizumab

  • Enzalutamide

  • CB-7598

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT02861573

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved